Abstract:BackgroundSomatostatin analogues, aiming to control tumor secretion or growth, constitute the most attractive therapeutic option for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The objective of this article is to provide a comprehensive review of the current state-of-the-art knowledge gaps and potential opportunities for future development and optimization of this therapeutic modality.MethodA contextualized systematic review with a narrative component was conducted using PubMed, The Cochrane Library, EMBASE, and Google Scholar. Titles were screened, and non-English, duplicate, or irrelevant entries were excluded. Selection criteria for articles included the following: publication in English between 1995 and 2016, patients with GEP-NETs, analysis of efficacy, safety, practical management considerations, predictive factors, and/or strategies for overcoming resistance, concerning somatostatin analogs.ResultsNinety-seven studies out of 2771 screened publications met the inclusion criteria (16 randomized clinical trials, 27 phase II trials, 3 phase I trials, 3 subgroup analyses of clinical trials, 1 open-label extension of a randomized trial, 1 phase IV trial, 32 observational studies, and 14 basic research articles). The nature and scope of literature was diverse with most articles dedicated to drug efficacy or indications of use (n = 49), pharmacological issues (n = 8), assessment or predictors of response (n = 4), practical management (n = 11), combination therapy or other means to overcome resistance (n = 19), receptors and signaling pathways (n = 3), and subgroup analyses (n = 3).ConclusionIn this appraisal, we have found some practical aspects that can help to the optimization of somatostatin analog (SSA) therapy in patients with well-differentiated GEP-NETs. We have also identified areas of uncertainty in an effort to guide clinical research in the coming years.

Agonists, Antagonists and Receptors of Somatostatin: Pathophysiological and Therapeutical Implications in Neoplasias

Versatile Functions of Somatostatin and Somatostatin Receptors in the Gastrointestinal System.

Somatostatin receptors: from signaling to clinical practice

The Role of Receptor-Ligand Interaction in Somatostatin Signaling Pathways: Implications for Neuroendocrine Tumors

Somatostatin receptors and the associated intracellular machinery: the two sides of the coin

Structure and Function of Somatostatin and its Receptors in Endocrinology

Somatostatin receptors in pituitary somatotroph adenomas as predictors of response to somatostatin receptor ligands: A pathologist's perspective

Somatostatin Receptor Based Imaging and Radionuclide Therapy

Relationship Between Somatostatin with Its Analogs and Pancreatic Cancer

Resistance of neuroendocrine tumours to somatostatin analogs

Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors

From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms

REGULATION OF SOMATOSTATIN RECEPTOR MESSENGER-RNA EXPRESSION

Expression of Somatostatin Receptors in Human Pancreatic Tumor

Selective ligand recognition and activation of somatostatin receptors SSTR1 and SSTR3

Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors.

The State-of-the-Art Mechanisms and Antitumor Effects of Somatostatin in Colorectal Cancer: A Review

Prospect of acromegaly therapy: molecular mechanism of clinical drugs octreotide and paltusotine

Truncated somatostatin receptors as new players in somatostatin-cortistatin pathophysiology

[Somatostatin and somatostatin receptors in the prostate]

Structural insights into ligand recognition and selectivity of somatostatin receptors